PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Drug Metabolism And Disposition

• Publication date

  2005-11-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.105.005884PMID 16081671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting drug-drug interactions in drug discovery: where are we now and where are we going?

  2005cited by this paper
• A UNIFIED MODEL FOR PREDICTING HUMAN HEPATIC, METABOLIC CLEARANCE FROM IN VITRO INTRINSIC CLEARANCE DATA IN HEPATOCYTES AND MICROSOMES

  2005cited by this paper
• Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.

  2005influential reference
• IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

  2005cited by this paper
• EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES

  2005cited by this paper
• Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6.

  2005cited by this paper
• THE BINDING OF DRUGS TO HEPATOCYTES AND ITS RELATIONSHIP TO PHYSICOCHEMICAL PROPERTIES

  2005cited by this paper
• EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE

  2004cited by this paper
• 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions.

  2004cited by this paper
• Qualitative and quantitative assessment of drug-drug interaction potential in man, based on Ki, IC50 and inhibitor concentration.

  2004cited by this paper
• Quantitative binding models for CYP2C9 based on benzbromarone analogues.

  2004influential reference
• Metabolic screening in vitro: metabolic stability, CYP inhibition and induction.

  2004cited by this paper
• An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.

  2004cited by this paper
• An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates.

  2004cited by this paper
• Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.

  2004cited by this paper
• Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.

  2003cited by this paper
• Drug metabolism and drug interactions: application and clinical value of in vitro models.

  2003cited by this paper
• In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.

  2003influential reference
• Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes.

  2003cited by this paper
• The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties.

  2002cited by this paper
• The potential pharmacological and toxicological impact of P450 screening.

  2001cited by this paper
• Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.

  2001cited by this paper
• The Use of Cultured Hepatocytes to Investigate the Metabolism of Drugs and Mechanisms of Drug Hepatotoxicity

  2001cited by this paper
• The potential pharmacological and toxicological impact of P450 screening.

  2001cited by this paper
• Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes

  2000cited by this paper
• Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes

  2000cited by this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999influential reference
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cited by this paper
• Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential.

  1999cited by this paper
• Overview: hepatocytes and cryopreservation--a personal historical perspective.

  1999cited by this paper
• Drug–drug interactions of new active substances: mibefradil example

  1999cited by this paper
• Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998influential reference
• Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.

  1998influential reference
• Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

  1998influential reference
• Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples.

  1998cited by this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cited by this paper
• Optic nerve decompression surgery not for NAION

  1995cited by this paper
• Cisapride and torsades de pointes

  1995cited by this paper
• Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.

  1993cited by this paper
• Epidemiology of Drug-Drug Interactions as a Cause of Hospital Admissions

  1993influential reference
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Development and Characterization of pFluor50, a Fluorogenic-Based Kinetic Assay System for High-Throughput Inhibition Screening and Characterization of Time-Dependent Inhibition and Inhibition Type for Six Human CYPs

  2023cites this paper
• 4.0. Species differences metabolism in vitro model of a novel analgesic propoxazepam with polymodal mechanism of

  2022cites this paper
• Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System

  2022cites this paper
• Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes)

  2019cites this paper
• Influences of Corydalis decumbens on the Activities of CYP450 Enzymes in Rats with a Cocktail Approach

  2019cites this paper
• Modeling Drug Disposition and Drug–Drug Interactions Through Hypothesis-Driven Physiologically Based Pharmacokinetics: a Reversal Translation Perspective

  2017cites this paper
• Inhibition of cytochrome P450 enzymes by saturated and unsaturated fatty acids in human liver microsomes, characterization of enzyme kinetics in the presence of bovine serum albumin (0.1 and 1.0% w/v) and in vitro – in vivo extrapolation of hepatic clearance

  2017cites this paper
• Prediction of Clinically Relevant Herb-Drug Clearance Interactions Using Sandwich-Cultured Human Hepatocytes: Schisandra spp. Case Study

  2017cites this paper
• Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam

  2017cites this paper
• Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast

  2017cites this paper
• Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug–drug interactions in rat liver

  2017cites this paper
• On-line coupling of immobilized cytochrome P450 microreactor and capillary electrophoresis: A promising tool for drug development.

  2016cites this paper
• Inhibitory effect of selected herbal supplements on CYP450-mediated metabolism : an in vitro approach

  2016cites this paper
• Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings

  2016cites this paper
• Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process

  2014cites this paper
• Clopidogrel: What Is a Cardiologist to Do?

  2014cites this paper
• A simplified approach to predict CYP3A-mediated drug–drug interactions at early drug discovery: validation with clinical data

  2013cites this paper
• Monoester-Diterpene Aconitum Alkaloid Metabolism in Human Liver Microsomes: Predominant Role of CYP3A4 and CYP3A5

  2013cites this paper
• In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability

  2013cites this paper
• New capillary electrophoretic method for on‐line screenings of drug metabolism mediated by cytochrome P450 enzymes

  2013cites this paper
• A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes

  2013cites this paper
• Evaluation of cytochrome P450-mediated drug–drug interactions based on the strategies recommended by regulatory authorities

  2012cites this paper
• Bioluminescent assays for ADME evaluation: dialing in CYP selectivity with luminogenic substrates

  2012cites this paper
• Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

  2012influential citation
• Predictions of CYP-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions

  2012cites this paper
• Methodologies used to identify and characterize interactions among antiepileptic drugs

  2012cites this paper
• Assessment of Compound Hepatotoxicity Using Human Plateable Cryopreserved Hepatocytes in a 1536-Well-Plate Format

  2012cites this paper
• Microsoft Word-32394427-file00.docx

  2012influential citation
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions.

  2010cites this paper
• Pharmacokinetic Drug Interaction between Carvedilol and Ticlopidine in Rats

  2010cites this paper
• Application of cytochrome P450 drug interaction screening in drug discovery.

  2010cites this paper
• Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions

  2010cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.

  2009cites this paper
• Plasma Protein Binding and Volume of Distribution: Determination, Prediction and Use in Early Drug Discovery

  2009cites this paper
• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I.

  2009cites this paper
• Drug–Drug Interactions with an Emphasis on Drug Metabolism and Transport

  2009cites this paper
• Multidrug Resistance Protein 2-Mediated Estradiol-17β-d-glucuronide Transport Potentiation: In Vitro-in Vivo Correlation and Species Specificity

  2009cites this paper
• New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.

  2009cites this paper
• The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo

  2008cites this paper
• Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes

  2008cites this paper
• Application of micellar electrokinetic capillary chromatography for evaluation of inhibitory effects on cytochrome P450 reaction.

  2008cites this paper
• An update on metabolism studies using human hepatocytes in primary culture.

  2008cites this paper
• Practice research in the field of gout - clinical pharmacology of antihyperuricemic drugs

  2008cites this paper
• Cytochrome P450s: Drug–Drug Interactions

  2008cites this paper
• An update on metabolism studies using human hepatocytes in primary culture

  2008cites this paper
• Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions

  2008influential citation
• Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction

  2008cites this paper
• Limited applicability of 7-methoxy-4-trifluoromethylcoumarin as a CYP2C9-selective substrate.

  2008cites this paper
• The pivotal role of hepatocytes in drug discovery.

  2007cites this paper
• Time-dependent CYP inhibition

  2007cites this paper
• EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES

  2006cites this paper
• Advances in predicting CYP-mediated drug interactions in the drug discovery setting

  2006cites this paper
• Prediction of In Vivo Drug-Drug Interactions from In Vitro Data

  2006cites this paper
• Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele?

  2006cites this paper
• Amiodarone Analog-Dependent Effects on CYP2C9-Mediated Metabolism and Kinetic Profiles

  2006influential citation
• Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.

  2006cites this paper